Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × lenvatinib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 12 Gastrointestinal 12 Gynecologic 7 Genitourinary 7 Tumor-Agnostic 6 Endocrine 6 Dermatologic 5 Thoracic 4 Sarcoma 4 CNS 4 Other solid neoplasm 3 Lymphoid 2 NET 1 Breast 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 14 Octreotide 7 lanreotide 5 Sunitinib 5 Magnetic Resonance Spectroscopy 5 lutetium Lu 177 dotatate 4 pasireotide 3 gallium Ga 68 dotatate 3 cabozantinib 3 arginyllysine 3 Temozolomide 3 Specimen Handling 3 Nivolumab 3 Etoposide 3 Carboplatin 3 Bevacizumab 3 telotristat ethyl 2 surufatinib 2 pembrolizumab 2 pazopanib 2 X-Rays 2 Phantoms, Imaging 2 Oxaliplatin 2 Ipilimumab 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Cisplatin 2 Capecitabine 2 3-Iodobenzylguanidine 2 177Lu-DOTA-JR11 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02678780 2025-07-24

TALENT

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

123 enrolled 37 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡